Skip to main content
SpringerLink
Log in

THC, CBD, and Anxiety: a Review of Recent Findings on the Anxiolytic and Anxiogenic Effects of Cannabis’ Primary Cannabinoids

  • Emotion and Addiction (K Morie, Section Editor)
  • Published:
Current Addiction Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

In the context of ongoing decriminalization and legalization of cannabis, a better understanding of how THC and CBD impact anxiety is critical to elucidate the risks of recreational cannabis use as well as to establish the therapeutic potential of cannabis products for anxiety-related applications.

Recent Findings

Recent literature supports anxiogenic effects of THC administration, which may be attenuated among regular cannabis users. Data regarding anxiolytic effects of CBD administration are mixed. Most newer studies contradict earlier findings in reporting no effects of CBD on anxiety in healthy participants, whereas inconsistent results have been reported among individuals with anxiety disorders, substance use disorders, and other clinical populations.

Summary

Future research is needed to reconcile heterogenous findings, explore sex differences in the effects of THC and CBD on anxiety, and to assess how effects change with extended exposure; the impact of different CBD doses, and the interactions between THC, CBD, and other cannabis compounds.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. World Drug Report 2021.

  2. SAMHSA. 2020 National Survey on Drug Use and Health: Detailed Tables. 2022.

  3. Martins SS, Levy NS, Bruzelius E, Segura LE. Cannabis legalization in the U.S. Where do we go from here? Trends Psychiatry Psychother. 2022;44(suppl 1):e20220001. https://doi.org/10.47626/2237-6089-2022-0001.

  4. Carliner H, Brown QL, Sarvet AL, Hasin DS. Cannabis use, attitudes, and legal status in the U.S. a review. Prev Med. 2017;104:13–23. https://doi.org/10.1016/j.ypmed.2017.07.008.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Mauro PM, Carliner H, Brown QL, Hasin DS, Shmulewitz D, Rahim-Juwel R, et al. Age differences in daily and nondaily cannabis use in the United States 2002–2014. J Stud Alcohol Drugs. 2018;79(3):423–31. https://doi.org/10.15288/jsad.2018.79.423.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Hasin DS, Sarvet AL, Cerda M, Keyes KM, Stohl M, Galea S, et al. US adult illicit cannabis use, cannabis use disorder, and medical marijuana lawS: 1991–1992 to 2012–2013. JAMA Psychiat. 2017;74(6):579–88. https://doi.org/10.1001/jamapsychiatry.2017.0724.

    Article  Google Scholar 

  7. Cerda M, Mauro C, Hamilton A, Levy NS, Santaella-Tenorio J, Hasin D, et al. Association between recreational marijuana legalization in the United States and changes in marijuana use and cannabis use disorder from 2008 to 2016. JAMA Psychiat. 2020;77(2):165–71. https://doi.org/10.1001/jamapsychiatry.2019.3254.

    Article  Google Scholar 

  8. Sexton M, Cuttler C, Finnell JS, Mischley LK. A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy. Cannabis Cannabinoid Res. 2016;1(1):131–8. https://doi.org/10.1089/can.2016.0007.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Lintzeris N, Driels J, Elias N, Arnold JC, McGregor IS, Allsop DJ. Medicinal cannabis in Australia, 2016: the Cannabis as Medicine Survey (CAMS-16). Med J Aust. 2018;209(5):211–6. https://doi.org/10.5694/mja17.01247.

    Article  PubMed  Google Scholar 

  10. Kosiba JD, Maisto SA, Ditre JW. Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: systematic review and meta-analysis. Soc Sci Med. 2019;233:181–92. https://doi.org/10.1016/j.socscimed.2019.06.005.

    Article  PubMed  Google Scholar 

  11. Wysota CN, Henriksen L, Romm KF, Duan Z, Wang Y, Huang J, et al. Cannabidiol knowledge, perceptions, and use among young adults in 6 U.S. metropolitan areas. Cannabis Cannabinoid Res. 2022. https://doi.org/10.1089/can.2022.0029.

  12. Gill LL. CBD Goes Mainstream. Consumer Reports. 2019.

  13. Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(12):995–1010. https://doi.org/10.1016/S2215-0366(19)30401-8.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Sharpe L, Sinclair J, Kramer A, de Manincor M, Sarris J. 2020 Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. J Transl Med.;18(1):374. https://doi.org/10.1186/s12967-020-02518-2. ([A review of earlier preclnical and clinical data on the effects of THC and CBD on anxiety.])

  15. Garcia-Gutierrez MS, Navarrete F, Gasparyan A, Austrich-Olivares A, Sala F, Manzanares J. 2020 Cannabidiol: a potential new alternative for the treatment of anxiety, depression, and psychotic disorders. Biomolecules.10(11). https://doi.org/10.3390/biom10111575.

  16. Sarris J, Sinclair J, Karamacoska D, Davidson M, Firth J. Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. BMC Psychiatry. 2020;20(1):24. https://doi.org/10.1186/s12888-019-2409-8.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015;12(4):825–36. https://doi.org/10.1007/s13311-015-0387-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Wright M, Di Ciano P, Brands B. Use of Cannabidiol for the treatment of anxiety: a short synthesis of pre-clinical and clinical evidence. Cannabis Cannabinoid Res. 2020;5(3):191–6. https://doi.org/10.1089/can.2019.0052.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kesner AJ, Lovinger DM. Cannabis use, abuse, and withdrawal: cannabinergic mechanisms, clinical, and preclinical findings. J Neurochem. 2021;157(5):1674–96. https://doi.org/10.1111/jnc.15369.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Boggs DL, Peckham A, Boggs AA, Ranganathan M. Delta-9-tetrahydrocannabinol and cannabidiol: separating the chemicals from the “weed”, a pharmacodynamic discussion. Ment Health Clin. 2016;6(6):277–84. https://doi.org/10.9740/mhc.2016.11.277.

    Article  PubMed  PubMed Central  Google Scholar 

  21. D’Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, et al. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology. 2008;33(10):2505–16. https://doi.org/10.1038/sj.npp.1301643.

    Article  CAS  PubMed  Google Scholar 

  22. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology. 1982;76(3):245–50. https://doi.org/10.1007/BF00432554.

    Article  CAS  PubMed  Google Scholar 

  23. Spindle TR, Cone EJ, Schlienz NJ, Mitchell JM, Bigelow GE, Flegel R, et al. 2018Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: a crossover trial. JAMA Netw Open.1(7):e184841. https://doi.org/10.1001/jamanetworkopen.2018.4841. ([Evaluated effects of THC administration on anxiety among healthy volunteers.])

  24. Sholler DJ, Strickland JC, Spindle TR, Weerts EM, Vandrey R. 2021 Sex differences in the acute effects of oral and vaporized cannabis among healthy adults. Addict Biol.26(4):e12968. https://doi.org/10.1111/adb.12968. ([Evaluated effects of THC administration on anxiety among healthy volunteers.])

  25. Bassir Nia A, Orejarena MJ, Flynn L, Luddy C, D'Souza DC, Skosnik PD, et al. 2022 Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC). Psychopharmacology (Berl).239(5):1621–8. https://doi.org/10.1007/s00213-022-06135-3. ([Assessed sex differences in anxiogenic effects of THC administration.])

  26. Arkell TR, Kevin RC, Vinckenbosch F, Lintzeris N, Theunissen E, Ramaekers JG, et al. 2022 Sex differences in acute cannabis effects revisited: results from two randomized, controlled trials. Addict Biol.27(2):e13125. https://doi.org/10.1111/adb.13125. ([Assessed sex differences in anxiogenic effects of THC administration.])

  27. Pabon E, Rockwood F, Norman GJ, de Wit H. 2022 Acute effects of oral delta-9-tetrahydrocannabinol (THC) on autonomic cardiac activity and their relation to subjective and anxiogenic effects. Psychophysiology.59(2):e13955. https://doi.org/10.1111/psyp.13955. ([Evaluated effects of THC administration on anxiety among healthy volunteers.])

  28. Matheson J, Sproule B, Di Ciano P, Fares A, Le Foll B, Mann RE, et al. 2020 Sex differences in the acute effects of smoked cannabis: evidence from a human laboratory study of young adults. Psychopharmacology (Berl).237(2):305–16. https://doi.org/10.1007/s00213-019-05369-y. ([Assessed sex differences in anxiogenic effects of THC administration.])

  29. Hurd YL. Leading the next CBD wave—safety and efficacy. JAMA Psychiat. 2020;77(4):341–2.

    Article  Google Scholar 

  30. Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimaraes FS. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci. 2012;367(1607):3364–78. https://doi.org/10.1098/rstb.2011.0389.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Campos AC, Fogaca MV, Scarante FF, Joca SRL, Sales AJ, Gomes FV, et al. Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders. Front Pharmacol. 2017;8:269. https://doi.org/10.3389/fphar.2017.00269.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Campos AC, Guimaraes FS. Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(8):1517–21. https://doi.org/10.1016/j.pnpbp.2009.08.017.

    Article  CAS  PubMed  Google Scholar 

  33. Zuardi AW, Rodrigues NP, Silva AL, Bernardo SA, Hallak JEC, Guimaraes FS, et al. Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol. 2017;8:259. https://doi.org/10.3389/fphar.2017.00259.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L, et al. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology. 2004;29(2):417–26. https://doi.org/10.1038/sj.npp.1300340.

    Article  CAS  PubMed  Google Scholar 

  35. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010;35(3):764–74. https://doi.org/10.1038/npp.2009.184.

    Article  CAS  PubMed  Google Scholar 

  36. Spindle TR, Cone EJ, Goffi E, Weerts EM, Mitchell JM, Winecker RE, et al. 2020 Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users. Drug Alcohol Depend.211:107937. https://doi.org/10.1016/j.drugalcdep.2020.107937. ([Evaluated effects of CBD on anxiety in healthy volunteers.])

  37. Bloomfield MAP, Yamamori Y, Hindocha C, Jones APM, Yim JLL, Walker HR, et al. 2022 The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study. Psychopharmacology (Berl).239(5):1539–49. https://doi.org/10.1007/s00213-022-06070-3. ([Evaluated effects of CBD on anxiety in healthy volunteers.])

  38. Linares IM, Zuardi AW, Pereira LC, Queiroz RH, Mechoulam R, Guimaraes FS, et al. 2019 Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Braz J Psychiatry.41(1):9–14. https://doi.org/10.1590/1516-4446-2017-0015. ([Evaluated effects of different CBD doses on anxiety in healthy volunteers.])

  39. Crippa JA, Pereira Junior LC, Pereira LC, Zimmermann PM, Brum Junior L, Rechia LM, et al. 2022 Effect of two oral formulations of cannabidiol on responses to emotional stimuli in healthy human volunteers: pharmaceutical vehicle matters. Braz J Psychiatry.44(1):15–20. https://doi.org/10.1590/1516-4446-2020-1684. ([Assessed anxiolytic effects of two CBD formulations among healthy volunteers.])

  40. Stanley TB, Ferretti ML, Bonn-Miller MO, Irons JG. 2022 A double-blind, randomized, placebo-controlled test of the effects of cannabidiol on experiences of test anxiety among college students. Cannabis Cannabinoid Res.https://doi.org/10.1089/can.2022.0062. ([Evaluated efficacy of CBD for reducing test anxiety among healthy college students.])

  41. Masataka N. 2019 Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Front Psychol.10:2466. https://doi.org/10.3389/fpsyg.2019.02466. ([Evaluated efficacy of chronic CBD administration for improving anxiety symptoms among adolescents with social anxiety disorder.])

  42. Bolsoni LM, Crippa JAS, Hallak JEC, Guimaraes FS, Zuardi AW. 2022 The anxiolytic effect of cannabidiol depends on the nature of the trauma when patients with post-traumatic stress disorder recall their trigger event. Braz J Psychiatry.44(3):298–307. https://doi.org/10.1590/1516-4446-2021-2317. ([Assessed whether CBD would attenuate anxiety induced by trauma recall among individuals with PTSD.])

  43. Kwee CM, Baas JM, van der Flier FE, Groenink L, Duits P, Eikelenboom M, et al. 2022 Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: a randomised controlled trial. Eur Neuropsychopharmacol. 59:58–67. https://doi.org/10.1016/j.euroneuro.2022.04.003. ([Evaluated CBD as an adjunct to in vivo exposure therapy among individuals with treatment refractory anxiety disorders.])

  44. Berger M, Li E, Rice S, Davey CG, Ratheesh A, Adams S, et al. 2022 Cannabidiol for treatment-resistant anxiety disorders in young people: an open-label trial. J Clin Psychiatry.83(5). https://doi.org/10.4088/JCP.21m14130. ([Assessed CBD as an add-on treatment for young people with treatment resistant anxiety disorders.])

  45. Hurd YL, Spriggs S, Alishayev J, Winkel G, Gurgov K, Kudrich C, et al. 2019 Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry.176(11):911–22. https://doi.org/10.1176/appi.ajp.2019.18101191. ([Assessed efficacy of multiple CBD doses for improving drug-cue-induced anxiety among individuals with heroin use disorder.])

  46. Freeman TP, Hindocha C, Baio G, Shaban NDC, Thomas EM, Astbury D, et al. 2020 Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry 7(10):865–74. https://doi.org/10.1016/S2215-0366(20)30290-X. ([Examined optimal dosing and efficacy of CBD for reducing cannabis use and anxiety symptoms among individuals with cannabis use disorder.])

  47. Mongeau-Perusse V, Rizkallah E, Morissette F, Brissette S, Bruneau J, Dubreucq S, et al. 2022 Cannabidiol effect on anxiety symptoms and stress response in individuals with cocaine use disorder: exploratory results from a randomized controlled trial. J Addict Med.https://doi.org/10.1097/ADM.0000000000000959. ([Assessed efficacy of CBD for reducing anxiety among individuals with cocaine use disorder.])

  48. Meneses-Gaya C, Crippa JA, Hallak JE, Miguel AQ, Laranjeira R, Bressan RA, et al. 2021 Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study. Braz J Psychiatry.43(5):467–76. https://doi.org/10.1590/1516-4446-2020-1416. ([Assessed efficacy of CBD for reducing anxiety among individuals with cocaine use disorder.])

  49. de Faria SM, de Morais FD, Tumas V, Castro PC, Ponti MA, Hallak JE, et al. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease. J Psychopharmacol. 2020;34(2):189–96. https://doi.org/10.1177/0269881119895536.

    Article  CAS  PubMed  Google Scholar 

  50. Appiah-Kusi E, Petros N, Wilson R, Colizzi M, Bossong MG, Valmaggia L, et al. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. Psychopharmacology. 2020;237(4):1121–30. https://doi.org/10.1007/s00213-019-05442-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Hundal H, Lister R, Evans N, Antley A, Englund A, Murray RM, et al. The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group. J Psychopharmacol. 2018;32(3):276–82. https://doi.org/10.1177/0269881117737400.

    Article  CAS  PubMed  Google Scholar 

  52. Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in anxiety and sleep: a large case series. Perm J. 2019;23:18–041. https://doi.org/10.7812/TPP/18-041.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Levinsohn EA, Hill KP. Clinical uses of cannabis and cannabinoids in the United States. J Neurol Sci. 2020;411: 116717. https://doi.org/10.1016/j.jns.2020.116717.

    Article  CAS  PubMed  Google Scholar 

  54. Sommano SR, Chittasupho C, Ruksiriwanich W, Jantrawut P. 2020 The cannabis terpenes. Molecules.25(24). https://doi.org/10.3390/molecules25245792.

  55. Ferber SG, Namdar D, Hen-Shoval D, Eger G, Koltai H, Shoval G, et al. The “entourage effect”: terpenes coupled with cannabinoids for the treatment of mood disorders and anxiety disorders. Curr Neuropharmacol. 2020;18(2):87–96. https://doi.org/10.2174/1570159X17666190903103923.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Schramm-Sapyta NL, Cha YM, Chaudhry S, Wilson WA, Swartzwelder HS, Kuhn CM. Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats. Psychopharmacology. 2007;191(4):867–77. https://doi.org/10.1007/s00213-006-0676-9.

    Article  CAS  PubMed  Google Scholar 

  57. Rubino T, Guidali C, Vigano D, Realini N, Valenti M, Massi P, et al. CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology. 2008;54(1):151–60. https://doi.org/10.1016/j.neuropharm.2007.06.024.

    Article  CAS  PubMed  Google Scholar 

  58. Fokos S, Panagis G. Effects of delta9-tetrahydrocannabinol on reward and anxiety in rats exposed to chronic unpredictable stress. J Psychopharmacol. 2010;24(5):767–77. https://doi.org/10.1177/0269881109104904.

    Article  CAS  PubMed  Google Scholar 

  59. Van Laere K, Goffin K, Casteels C, Dupont P, Mortelmans L, de Hoon J, et al. Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET. Neuroimage. 2008;39(4):1533–41. https://doi.org/10.1016/j.neuroimage.2007.10.053.

    Article  PubMed  Google Scholar 

  60. Nadulski T, Pragst F, Weinberg G, Roser P, Schnelle M, Fronk EM, et al. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Ther Drug Monit. 2005;27(6):799–810. https://doi.org/10.1097/01.ftd.0000177223.19294.5c.

    Article  CAS  PubMed  Google Scholar 

  61. Haney M, Malcolm RJ, Babalonis S, Nuzzo PA, Cooper ZD, Bedi G, et al. Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis. Neuropsychopharmacology. 2016;41(8):1974–82. https://doi.org/10.1038/npp.2015.367.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Stack SK, Wheate NJ, Schubert EA. Medicinal cannabis for the treatment of anxiety disorders: a narrative review. Current Treatment Options in Psychiatry. 2022;9(3):163–73. https://doi.org/10.1007/s40501-022-00260-8.

    Article  Google Scholar 

  63. Yamagata K, Sugimura M, Yoshida M, Sekine S, Kawano A, Oyamaguchi A, et al. Estrogens exacerbate nociceptive pain via up-regulation of TRPV1 and ANO1 in trigeminal primary neurons of female rats. Endocrinology. 2016;157(11):4309–17. https://doi.org/10.1210/en.2016-1218.

    Article  CAS  PubMed  Google Scholar 

  64. Cooper ZD, Craft RM. Sex-dependent effects of cannabis and cannabinoids: a translational perspectivE. Neuropsychopharmacology. 2018;43(1):34–51. https://doi.org/10.1038/npp.2017.140.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

Funding for this work was provided by NIDA K08DA051667 and Women’s Health Research at Yale (WHRY).

Author information

Authors and Affiliations

  1. Department of Psychiatry, Yale School of Medicine, 40 Temple Street, Suite 6C #626, New Haven, CT, 06510, USA

    Sarah D. Lichenstein

Authors
  1. Sarah D. Lichenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah D. Lichenstein.

Ethics declarations

Competing Interests

The author declares no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Emotion and Addiction

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lichenstein, S.D. THC, CBD, and Anxiety: a Review of Recent Findings on the Anxiolytic and Anxiogenic Effects of Cannabis’ Primary Cannabinoids. Curr Addict Rep 9, 473–485 (2022). https://doi.org/10.1007/s40429-022-00450-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40429-022-00450-7

Keywords

Search

Navigation